| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.074 | 0.2 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.2 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.2 |